Topic:

R&D

Latest Headlines

Latest Headlines

Bristol-Myers' nivolumab impresses once again--this time in crucial lung cancer study

Bristol-Myers Squibb's closely watched checkpoint inhibitor nivolumab managed to wow analysts this morning with impressive survival results in a Phase II study of patients with advanced squamous cell non-small cell lung cancer. Of all the patients in the drug arm, 41% were alive at the one-year mark, while investigators tracked an overall response rate of 15%.

Nintendo developing cloud-based sleep-monitoring device amid market growth

As med tech companies roll out innovative products to treat sleep disorders, electronics outfit Nintendo is looking to cash in on the trend with a new sleep-monitoring device that runs on its health-focused platform.

Cleveland Clinic toasts Novartis, PCSK9ers and immuno-oncology in its R&D top 10

The Cleveland Clinic's annual list of the most promising medical innovations reads a bit like a biopharma yearbook, name-checking a slew of potential blockbuster treatments and affirming the potential of some of the biggest targets in drug development.

GE Healthcare opens first health tech incubator

GE Healthcare has opened its first health tech startup campus at its Finland headquarters in Helsinki. It's already home to 20 health tech startups working on wireless technologies, sensors, apps and cloud services to improve healthcare.

Microscale fibers may have many drug-delivery uses

Drug delivery researchers are probing the depths of nanotechnology. However, researchers at New York University have shown that the maxim "better is better" can be true in the drug-delivery world as well, due to the development of drug delivering fibers that are the diameter of spider silk.

Harvard team uses stem cells to deliver toxic doses to cancer cells

Researchers at Harvard have programmed stem cells embedded in a tumor to deliver a toxic dose of cytotoxins, killing the cancer cells from the inside.

BDSI aiming to develop injectable buprenorphine

BioDelivery Sciences International is partnering with Evonik to develop a formulation of buprenorphine that can be subcutaneously injected and provide continuous therapy for 30 days. BDSI will pursue an approval for opioid dependence in about three years, but also aims to develop a product for chronic pain in patients requiring continuous opioid therapy.

J&J Innovation's Ken Drazan on the future of med tech

Ken Drazan, the head of Johnson & Johnson's California Innovation Center, sat down with FierceMedicalDevices to muse on the company's interest in med tech.

Medtronic announces first U.S. implant of investigational aortic heart valve

Medtronic announced that its investigational aortic heart valve made using cow heart tissue has been implanted in its first U.S. patient, as the global, five-year Perigon trial of 650 patients gathers steam. It will be conducted at 40 sites in Europe, the U.S. and Canada.

Armed with $48M bankroll, Aileron sets sights on p53 tumor target

Aileron Therapeutics has gone back to the well of investor cash and drawn up another $18 million in fresh support for its soon-to-launch, early-stage study of a p53 targeting cancer therapy.